Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX) from its SEC filings: 2025 revenue $84.0 million (+54% vs the year before), net margin -315%, free cash flow -$263.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $84.0 million |
| Revenue growth | +54% |
| Net income | -$264.5 million |
| Net margin | -314.9% |
| Free cash flow | -$263.5 million |
| Diluted EPS | $-3.05 |
| Latest quarter (Q3 2026 (calendar)) revenue vs a year earlier | +8426% |
| Cash | $720.2 million |
| Share count, 1 year | +42% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.